Skip To The Main Content

U.S. FDA Continues Data Integrity Focus

July August 2019

A Review of U.S. Regulations on cGMP and Data Integrity

The U.S. FDA continues to inspect pharmaceutical facilities for compliance with cGMP regulations, and as a result of these inspections, has issued numerous warning letters citing several significant violations involving data integrity.